BioSpace News Archive

Anticancer Bioscience, pioneers in synthetic lethal approaches to precision oncology, announced that having successfully closed an additional financing round, raising CNY63m, it has already achieved positive animal data in its small molecule program targeting MYC overexpression.

CareCapital Advisors Limited announces the appointment of Mr. A P A Bindusaran as Executive Director and Head of DSO Clinical and Business Development.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus, announced the expansion of its R&D pipeline with six new armed gene therapy/oncolytic constructs directed against important cancer targets and indications.

NanoViricides, Inc. has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

GENETWORx Laboratories has announced accelerated testing times of only 8-12 hours on average for molecular diagnostic, or PCR testing, of COVID-19 specimens at its new mobile laboratories

These Additional Classifications are: Tauri-Gum™ Cases (8 Retail Boxes) & Tauri-Gum™ Shipment Crates (48 Retail Boxes)

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced the appointment of William H. Carson, M.D. to its board of directors.

NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: Avenova®, the premier antimicrobial lid and lash spray, and CelleRx® Clinical Reset, a breakthrough product that marked our entry into a new beauty category late last year.

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03,

Targeting initiation of dose confirmation trial by end of 2021 with data readout by end of 2022 Initiation of Phase 3 pivotal trial targeted by mid-2023, with data readout and BLA filing targeted by end of 2024